Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions
In brief
Merck’s new commitment to mRNA cancer vaccines raises the stakes for Pfizer’s oncology ambitions, potentially reshaping the competitive dynamics of the mRNA‑oncology market.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.